Theragen Etex Co.,Ltd. (KOSDAQ:066700)
South Korea · Delayed Price · Currency is KRW 2,265.00
-5.00 (-0.22%)
At close: Oct 2, 2026
Theragen Etex Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 275,358 | 271,590 | 249,625 | 216,470 | 190,769 | 166,567 |
Revenue Growth | 6.13% | 8.80% | 15.32% | 13.47% | 14.53% | 16.46% |
Gross Profit Gross Profit Growth | 143,401 | 141,013 | 125,981 | 100,126 | 77,406 | 61,175 |
Operating Income Operating Income Growth | 10,778 | 10,213 | 11,646 | 11,473 | 11,853 | -7,427 |
Net Income Net Income Growth | 1,251 | 10,600 | -40,985 | 26,211 | 9,561 | -11,854 |
Earnings Per Share EPS Growth | 34.09 | 290.16 | -1281.00 | 818.97 | 297.86 | -371.00 |
EPS Growth | - | - | - | 174.95% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceutical Business Pharmaceutical Business Growth | 259,759 | 257,795 | 236,309 | 203,309 | 170,807 | 144,465 |
Health Care and Genome Analysis Business Health Care and Genome Analysis Business Growth | 16,361 | 14,748 | 18,648 | 20,992 | 24,472 | 22,999 |
Consolidation Adjustment Journal Entry Consolidation Adjustment Journal Entry Growth | -762.32 | -952.59 | -1,365 | -1,236 | -1,900 | -896.67 |
Suspended Business Suspended Business Growth | - | - | -3,966 | -6,595 | -2,610 | - |
Total Total Growth | 275,358 | 271,590 | 249,625 | 216,470 | 190,769 | 166,567 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 41,354 | 38,025 | 24,183 | 23,280 | 21,421 | 13,602 |
Total Debt Total Debt Growth | 42,047 | 41,645 | 50,476 | 36,297 | 31,222 | 36,743 |
Net Cash (Debt) Net Cash Growth | -693.38 | -3,620 | -26,293 | -13,016 | -9,801 | -23,141 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -18.39 | -98.43 | -821.52 | -406.70 | -306.23 | -723.30 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 13,937 | 10,972 | 1,788 | 12,125 | 9,593 | 4,007 |
Capital Expenditures CapEx Growth | -3,531 | -2,576 | -11,392 | -4,797 | -4,193 | -2,749 |
Free Cash Flow Free Cash Flow Growth | 10,406 | 8,396 | -9,604 | 7,328 | 5,401 | 1,257 |
Free Cash Flow Growth | - | - | - | 35.69% | 329.54% | -87.69% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 52.08% | 51.92% | 50.47% | 46.25% | 40.58% | 36.73% |
Operating Margin | 3.91% | 3.76% | 4.67% | 5.30% | 6.21% | -4.46% |
Pretax Margin | 1.88% | 6.46% | -17.29% | 15.13% | 7.26% | -7.61% |
Profit Margin | 0.45% | 3.90% | -16.42% | 12.11% | 5.01% | -7.12% |
FCF Margin | 3.78% | 3.09% | -3.85% | 3.38% | 2.83% | 0.76% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 66.44 | 10.94 | - | 5.46 | 14.80 | - |
Forward PE | - | 111.48 | 111.48 | 111.48 | 111.48 | 111.48 |
P/FCF Ratio | 7.98 | 13.81 | - | 19.52 | 26.19 | 163.17 |
PS Ratio | 0.30 | 0.43 | 0.40 | 0.66 | 0.74 | 1.23 |